Axcan will now await FDA approval, the final step before marketing the drug. The FDA's decision is expected quickly, possibly near the end of the present year or early in 1997. PBC is a chronic, progressive cholestatic liver disease of unknown origin. Some 50,000 people in the United States have the disease. At present, after diagnosis, patients survive an average of 10 years.
Liver transplant is the only current treatment modality for end-stage patients.
It improves the survival rate of patients free of liver transplantation and improves liver biochemistry. Use of this site signifies your agreement to the terms of use.